Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.

Kahl BS, Bailey HH, Smith EP, Turman N, Smith J, Werndli J, Williams EC, Longo WL, Kim KM, McGovern J, Jumonville A.

Cancer Invest. 2005;23(1):13-8.

PMID:
15779863
2.

Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.

Casasnovas RO, Haioun C, Dumontet C, Gabarre J, Richard B, Lederlin P, Caillot D, Stamatoullas A, Morel P, Quesnel B, Blay JY, Bouabdallah K, Gisselbrecht C.

Haematologica. 2000 May;85(5):502-7.

3.

Phase II study of paclitaxel and estramustine in patients with recurrent and refractory non-Hodgkin lymphoma.

Borghaei H, Millenson M, Schilder R, Alden M, Rogatko A, Wang H, Padavic-Shaller K, Smith MR.

Cancer. 2004 Nov 1;101(9):2034-41.

4.

Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.

Rizzieri DA, Sand GJ, McGaughey D, Moore JO, DeCastro C, Chao NJ, Vredenburgh JJ, Gasparetto C, Long GD, Anderson E, Foster T, Toaso B, Adams D, Niedzwiecki D, Gockerman JP.

Cancer. 2004 Jun 1;100(11):2408-14.

5.

Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.

Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, Preti A, Bachier C, Smith T, Cabanillas F.

Br J Haematol. 1997 Feb;96(2):328-32.

PMID:
9029021
7.

The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.

Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M.

Cancer J. 2005 May-Jun;11(3):209-16.

PMID:
16053664
8.

High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma.

Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M.

Clin Cancer Res. 2006 Sep 1;12(17):5190-8.

9.

Long-term, weekly one-hour infusion of paclitaxel in patients with metastatic breast cancer: a phase II monoinstitutional study.

Lombardi D, Crivellari D, Scuderi C, Magri MD, Spazzapan S, Sorio R, Di Lauro V, Scalone S, Veronesi A.

Tumori. 2004 May-Jun;90(3):285-8.

PMID:
15315306
10.

Combined results of two phase II studies of Taxol (paclitaxel) in patients with relapsed or refractory lymphomas.

Goss P, Stewart AK, Couture F, Klasa R, Gl├╝ck S, Kaizer L, Burkes R, Charpentier D, Palmer M, Tye L, Dulude H.

Leuk Lymphoma. 1999 Jul;34(3-4):295-304.

PMID:
10439366
11.

Infusional vinorelbine in relapsed or refractory lymphomas.

Sarris AH, Psyrri A, Hagemeister F, Romaguera J, McLaughlin P, Rodriguez MA, Bachier C, Younes A, Mesina O, Oholendt M, Medeiros LJ, Samuels B, Adams LM, Cabanillas F.

Leuk Lymphoma. 2000 Oct;39(3-4):291-9.

PMID:
11342309
12.

A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease.

Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE.

Anticancer Drugs. 1998 Feb;9(2):135-40.

PMID:
9510499
13.

A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.

Kraut EH, Balcerzak SP, Young D, Davis MP, Jacobs SA; Ohio State University Phase II Reseeearch Consortium Study.

Cancer Invest. 2002;20(2):174-9.

PMID:
11901536
14.

Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.

Pro B, Hagemeister FB, McLaughlin P, Romaguera J, Rodriguez MA, Cabanillas F, Tiongson LP, Younes A.

Leuk Lymphoma. 2006 Sep;47(9):1818-21.

PMID:
17064994
15.

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.

Linch M, Stavridi F, Hook J, Barbachano Y, Gore M, Kaye SB.

Gynecol Oncol. 2008 Apr;109(1):27-32. doi: 10.1016/j.ygyno.2008.01.007. Epub 2008 Feb 8.

PMID:
18262259
16.

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy.

Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, Ette E, Garg V, Fuller A, Harding MW, Charpentier D.

Gynecol Oncol. 2002 Sep;86(3):302-10.

PMID:
12217752
17.
18.

Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma.

Oki Y, McLaughlin P, Pro B, Hagemeister FB, Bleyer A, Loyer E, Younes A.

Cancer. 2005 Aug 15;104(4):781-7.

19.

A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.

Pignata S, Breda E, Scambia G, Pisano C, Zagonel V, Lorusso D, Greggi S, De Vivo R, Ferrandina G, Gallo C, Perrone F.

Crit Rev Oncol Hematol. 2008 Jun;66(3):229-36. doi: 10.1016/j.critrevonc.2007.12.005. Epub 2008 Feb 1.

PMID:
18243011
20.

Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.

Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M.

Anticancer Res. 2006 Jan-Feb;26(1B):777-81.

Supplemental Content

Support Center